Protein / target

DNA-directed RNA polymerase subunit alpha

rpoAQ18CI5Clostridioides difficile (strain 630)Swiss-Prot

UniProt: Q18CI5 NCBI Gene: 66352600

Clinical trials

Drugs targeting

Protein at a glance

Biological role

DNA-directed RNA polymerase activity

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates

Domains and Gene Ontology detail (6)

Gene Ontology

Ccytoplasm
CDNA-directed RNA polymerase complex
FDNA binding
FDNA-directed RNA polymerase activity
Fprotein dimerization activity
PDNA-templated transcription

315 aa · 35 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO

View supporting evidence

Transcriptional regulation

·DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four…
·DNA-templated transcription

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Fidaxomicin

Inhibitor

DNA-directed RNA polymerase inhibitor

Acts on a complex — shared with rpoB, rpoC, rpoZ · 1 of 4 recorded protein targets

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

An Open-label, Randomized Study to Assess Inhibition of Spore Production in Patients With Clostridium Difficile Infections: Fidaxomicin Versus VancomycinPHASE4

COMPLETED · via Fidaxomicin · NCT01818141

A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive TherapyPHASE4

TERMINATED · via Fidaxomicin · NCT01775397

CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile InfectionPHASE4

TERMINATED · via Fidaxomicin · NCT02667418

Exploratory Study of Impact of Oral Metronidazole, Vancomycin and Fidaxomicin on the Extent and Quantity of Host Carriage and Environmental Contamination With C. DifficilePHASE4

COMPLETED · via Fidaxomicin · NCT02057198

Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile InfectionPHASE4

TERMINATED · via Fidaxomicin · NCT02355938

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian SubjectsPHASE1

COMPLETED · via Fidaxomicin · NCT01813448

Show remaining trials (18)

A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects With Clostridium Difficile-associated DiarrheaPHASE3

COMPLETED · via Fidaxomicin · NCT02218372

A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older PopulationPHASE4

COMPLETED · via Fidaxomicin · NCT02254967

A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated DiarrheaPHASE3

COMPLETED · via Fidaxomicin · NCT00314951

DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell TransplantationPHASE3

COMPLETED · via Fidaxomicin · NCT01691248

A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)PHASE2

COMPLETED · via Fidaxomicin · NCT02784002

The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk PatientsPHASE4

WITHDRAWN · via Fidaxomicin · NCT01552668

A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic InfectionsPHASE4

COMPLETED · via Fidaxomicin · NCT02692651

Multicenter, Randomized, Open-label, Three-arm Study on the Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in the Treatment and Relapse Prophylaxis of Clostridioides Difficile Infection. STOP-CDI StudyNA

NOT_YET_RECRUITING · via Fidaxomicin · NCT07120490

Prospective, Open-label Trial to Evaluate Efficacy of 30-day Duration of Fidaxomicin in Patients With Recurrent C. Difficile InfectionPHASE3

TERMINATED · via Fidaxomicin · NCT02395848

Serial Fecal Microbiota Transplant (FMT) Plus Fidaxomicin in the Treatment of Severe or Fulminant Clostridium Difficile Infection, With Detailed Characterization in Microbiota, Metabolomics and Host Immune ResponsePHASE2

TERMINATED · via Fidaxomicin · NCT03760484

A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.PHASE3

COMPLETED · via Fidaxomicin · NCT05201079

Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)PHASE4

COMPLETED · via Fidaxomicin · NCT02437591

A Phase 1, Open Label, Randomized, Two-way Crossover Study to Evaluate the Effect of Multiple Doses of Fidaxomicin on the Single Dose Pharmacokinetics of Rosuvastatin in Healthy Male SubjectsPHASE1

COMPLETED · via Fidaxomicin · NCT02083627

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel DiseasePHASE4

NOT_YET_RECRUITING · via Fidaxomicin · NCT06794944

Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile InfectionPHASE4

WITHDRAWN · via Fidaxomicin · NCT02464306

Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides Difficile Infection 2: A Randomized Controlled TrialPHASE3

RECRUITING · via Fidaxomicin · NCT07328971

A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)PHASE2

COMPLETED · via Fidaxomicin · NCT01591863

Fecal Microbiota Transplantation for Relapsing Clostridium Difficile InfectionPHASE3

COMPLETED · via Fidaxomicin · NCT02743234

ClinicalTrials.gov via the drug-target graph.

What's happening now

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

New publication2018-08-01
Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.
Journal of the Pediatric Infectious Diseases Society · 2018 · 18 citations · Europe PMC · via Fidaxomicin
Regulatory approval2011-12-05
Approval: Dificlir (EMA)
ema · regulatory · ema · via Fidaxomicin
New publication2011-02-01
Fidaxomicin versus vancomycin for Clostridium difficile infection.
The New England journal of medicine · 2011 · 1,120 citations · Europe PMC · via Fidaxomicin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.